With 8.49 million shares changed hands, the volume of the stock remained heavier than its average volume of 27150.0 shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.06 whereas the lowest price it dropped to was $0.6402. The 52-week range on CHEK shows that it touched its highest point at $3.04 and its lowest point at $0.56 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.36.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CHEK was up-trending over the past week, with a rise of 13.92%, but this was down by -0.81% over a month. Three-month performance dropped to -10.19% while six-month performance fell -8.46%. The stock lost -25.86% in the past year, while it has lost -61.37% so far this year.
Float and Shares Shorts:
At present, 5.85 million CHEK shares are outstanding with a float of 4.39 million shares on hand for trading. In addition to Dr. Yoav Kimchy Ph.D. as the firm’s Founder, Head of R&D and Member of Scientific Advisory Board, Mr. David Lontini serves as its Interim CEO & Chairman of the Board.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, CHEK reported revenue of $0.0 and operating income of -$3991000.0.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.51 being high and -$2.51 being low. For CHEK, this leads to a yearly average estimate of -$2.51. The surprise factor in the prior quarter was -$0.53.
